Supplementary Figure S1 from A Phase II Open-Label Randomized Clinical Trial of Preoperative Durvalumab or Durvalumab plus Tremelimumab in Resectable Head and Neck Squamous Cell Carcinoma

Key Points

The trial evaluates the effects of durvalumab and tremelimumab on head and neck squamous cell carcinoma.
Participants received either durvalumab or durvalumab plus tremelimumab before surgery in an open-label setting.
Investigating immunotherapy approaches could improve patient outcomes in resectable cancers.
The findings may inform future therapeutic strategies, highlighting the importance of combination therapies.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Randomized clinical trial assesses preoperative durvalumab and tremelimumab, suggesting potential treatment strategies.

Trial scheme.

No takes yet. Share an insight, caveat, or question.

Kim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share